Bailey Gregory 4

What Happened

• Bailey Gregory, a director of Biohaven Ltd. (BHVN), was granted a derivative equity award on 2026-04-28 covering 68,693 shares. The acquisition is reported as $0 at grant (derivative), meaning no cash was exchanged at the time of the award. This is an equity compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-28; Form 4 filed: 2026-04-30 (timely filing under Form 4 rules).
• Transaction type/code: Grant/Award (A); reported as a derivative instrument (stock option).
• Shares involved: 68,693 option shares; reported acquisition value: $0 (no cash paid at grant).
• Vesting: The award vests in full on the earlier of (a) April 28, 2027 or (b) the 2027 Annual Meeting of Shareholders, subject to continuous service (see footnote).
• Exercise price and post-transaction beneficial ownership were not provided in the excerpt; consult the full Form 4 (Accession No. 0001329505-26-000005) for those details.

Context

• This was an option/award grant (compensation), not a market purchase or sale. Such grants are commonly used to retain executives/directors and do not by themselves indicate immediate buying or selling pressure. For investors seeking impact on ownership or potential future dilution, check the full filing for exercise price and total shares owned following the grant.